Related Experiment Video

Updated: May 26, 2026

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Targeting the S and G2 checkpoint to treat cancer

Tao Chen1, Peter A Stephens, Fiona K Middleton

  • 1Newcastle University, Northern Institute for Cancer Research, Newcastle-upon-Tyne, UK.

Drug Discovery Today
|December 24, 2011
PubMed

Insights

Inhibiting ATR or Chk1, crucial for cancer cell cycle arrest after DNA damage, can selectively sensitize tumors to therapies. This approach enhances cancer cell death and may exploit synthetic lethality in DNA repair-deficient cells.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Cycle Regulation

Background:

  • Cell survival post-DNA damage relies on cell cycle checkpoints to halt proliferation.
  • Cancer cells often exhibit G1 checkpoint dysregulation, increasing reliance on S and G2 checkpoints.
  • The ATR/Chk1 signaling pathway is critical for activating these essential S and G2 checkpoints.

Purpose of the Study:

  • To investigate the potential of inhibiting ATR (Ataxia Telangiectasia and Rad3-related) or Chk1 (Checkpoint Kinase 1) as a targeted cancer therapy.
  • To determine if blocking ATR/Chk1 signaling selectively sensitizes cancer cells to DNA-damaging agents.
  • To explore the possibility of synthetic lethality in tumors with impaired DNA repair pathways.

Main Methods:

  • Genetic inactivation of ATR and Chk1 genes.
  • Treatment with small-molecule ATR and Chk1 inhibitors.
  • Assessment of cell cycle arrest and cytotoxicity following exposure to DNA-damaging agents.
  • In vitro studies on cancer cell lines.

Main Results:

  • Genetic inactivation of ATR and Chk1 led to abrogated cell cycle arrest and increased cytotoxicity.
  • Small-molecule Chk1 inhibitors demonstrated similar sensitizing effects in preclinical studies.
  • Potent ATR inhibitors were identified that sensitize cancer cells in vitro.
  • Emerging clinical trial data support the therapeutic potential of these inhibitors.

Conclusions:

  • Inhibiting ATR or Chk1 selectively sensitizes cancer cells to DNA-damaging agents by disrupting critical checkpoints.
  • ATR and Chk1 inhibitors represent a promising therapeutic strategy for various cancers.
  • These inhibitors may induce synthetic lethality in tumors with specific DNA repair defects, offering novel treatment avenues.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Temporal Tracking of Cell Cycle Progression Using Flow Cytometry without the Need for Synchronization08:52

Temporal Tracking of Cell Cycle Progression Using Flow Cytometry without the Need for Synchronization

Published on: August 16, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Cell Cycle Control System01:28

The Cell Cycle Control System

The cell cycle regulation directs how a cell proceeds from one phase to the next and begins mitosis. The cell cycle control system includes intracellular regulatory molecules and external triggers. They provide "stop" or "advance" signals and operate at specific cell cycle stages termed checkpoints to ensure that a particular process is completed before the cell advances to the next phase.
Cyclins and cyclin-dependent kinases (Cdks) are the primary cell cycle regulators and function at the cell...
The Cell Cycle Control System02:11

The Cell Cycle Control System

The cell cycle is an organized set of events that leads the cell to divide into two daughter cells, each containing chromosomes identical to the parent cell. It is the cell cycle that leads to the formation of an entire organism from a single-cell zygote. Besides, cell division also functions in the renewal or repair of tissues in adult multicellular eukaryotes. For example, in the bone marrow, the stem cells divide to form new blood cells. Although essential for several functions, cell...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...